ZNF346

Across TCGA pan-cancer cohorts, ZNF346 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF346 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ZNF346 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF346 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, SKCM, and UCEC are the cancer types where ZNF346 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.096	0.688	<.001	12	view →
SKCM	OS	Median	All	0.245	0.781	.008	12	view →
UCEC	DFS	Median	All	1.000	0.621	.015	10	view →
SARC	DFS	Median	All	0.165	0.612	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF346–STAD (OS)

Open the STAD breakdown →